Clinical Trial

Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)

Study acronym: HypoElect
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI). All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-30; most recent amendment 2025-03-10.
Trial Details
NCT Number NCT06582446
Lead Sponsor German Oncology Center, Cyprus
Conditions Prostate Cancer
Enrollment 30 participants
Start Date 2024-09-16
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-11